The Workers Compensation Board of Manitoba reviews ketamine and esketamine treatment requests on a case-by-case basis. Unlike WSIB (Workplace Safety and Insurance Board) Ontario or WCB (Workers' Compensation Board) Alberta, WCB Manitoba does not maintain a formal published formulary listing or procedure document specific to ketamine for compensable PTSD (post-traumatic stress disorder) or chronic pain. What Manitoba does offer is the broadest first-responder PTSD presumption in Canada, a regulator (the College of Physicians and Surgeons of Manitoba) that updated its non-hospital facility framework in January 2026, and a small but established clinical infrastructure in Winnipeg for ketamine-assisted treatment. This guide explains how those pieces fit together for injured Manitoba workers and first responders.

Key takeaways

WCB Manitoba reviews ketamine and esketamine claims case-by-case. There is no formal listing or published procedure comparable to WSIB Ontario's drug formulary or WCB Alberta's Procedure 4-12.

Manitoba was the first Canadian province to enact presumptive PTSD legislation for first responders. The Workers Compensation Amendment Act (Presumption re Post-Traumatic Stress Disorder) was passed in January 2016 and came into force in June 2016.

A 2018 expansion gave Manitoba the broadest presumptive PTSD scope in Canada, extending coverage beyond designated first-responder occupations to any worker exposed to a traumatic event under specific conditions.

The College of Physicians and Surgeons of Manitoba (CPSM) updated its non-hospital facility framework in January 2026. The framework governs how ketamine therapy is delivered in non-hospital community settings.

There is no publicly funded outpatient psychiatric ketamine programme in Manitoba in 2026. Health Sciences Centre (HSC) and St. Boniface Hospital handle inpatient mental health care. Outpatient ketamine-assisted therapy is delivered through private clinics.

Manitoba Pharmacare lists Spravato (esketamine) as a non-benefit, which limits public reimbursement and increases reliance on WCB approval or private payment for compensable workers.

ATMA CENA's Manitoba member clinic is NeuroMed Wellness Clinic in Winnipeg, with ketamine-assisted therapy delivered through coordinated care partnership.

What WCB Manitoba covers for psychedelic-assisted therapy

WCB Manitoba's Healthcare Services policy authorises payment for healthcare services that are reasonably required to address the effects of a workplace injury [WCB Manitoba 2024]. Coverage decisions for non-formulary, off-label, or specialty interventions are made case-by-case by WCB Manitoba's medical advisors, in consultation with the worker's treating physicians.

Unlike WSIB Ontario, which lists ketamine HCl injection on five specialty formularies and esketamine on two, and unlike WCB Alberta, which maintains a documented Pharmaceutical Ketamine and Esketamine procedure (Procedure 4-12), WCB Manitoba does not publish a formal listing for ketamine or esketamine. Coverage requests are evaluated through the standard healthcare services adjudication process. The treating physician submits a request with supporting clinical documentation, and a WCB medical advisor reviews the file.

In practice, this means three things for injured Manitoba workers:

Coverage is genuinely case-by-case. There is no published checklist of formulary criteria to meet, no specific form analogous to Alberta's Form C1520, and no public formulary table that confirms a "yes" if the worker fits the criteria.
Clinical documentation does the heavy lifting. The treating physician's clinical rationale, the documented failure of conventional treatments, and the alignment of the proposed treatment with the compensable injury are the determining factors.
Outcomes vary by claim. Two workers with similar diagnoses and similar treatment histories may receive different decisions depending on the medical advisor's review, the comprehensiveness of the documentation, and the specific compensable context.

Psilocybin and MDMA are not listed by WCB Manitoba. These substances are restricted drugs under Canada's Controlled Drugs and Substances Act, and patient access is available only through Health Canada's Special Access Program (SAP), on a case-by-case basis. SAP approval is not guaranteed, and approval rates declined approximately 50% in 2025 [PsyCan 2025; Health Canada SAP]. The realistic 2026 pathway for WCB-covered psychedelic-assisted therapy in Manitoba involves ketamine and esketamine specifically.

For a cross-provincial comparison of workers' compensation coverage for psychedelic-assisted therapy, see the workers' compensation and psychedelic-assisted therapy guide for Canada and the broader insurance coverage for psychedelic-assisted therapy in Canada overview.

Manitoba's presumptive PTSD legislation: Canada's first, and broadest

Manitoba was the first Canadian province to enact presumptive PTSD legislation. The Workers Compensation Amendment Act (Presumption re Post-Traumatic Stress Disorder) passed the Manitoba Legislature in January 2016 and came into force on June 9, 2016 [Manitoba 2015; WCB Manitoba 2016]. The legislation establishes that PTSD diagnosed in a worker exposed to a traumatic event in the course of their employment is presumed to be work-related, unless the contrary is proven.

The 2016 framework

The original 2016 legislation covered the standard set of designated first responders:

Firefighters (full-time, part-time, and volunteer)
Police officers
Paramedics
Corrections officers
Emergency medical services dispatchers
Sheriffs
Selected other workers exposed to traumatic events in the course of duty

What set Manitoba's framework apart from later provincial schemes was its non-occupational test. Where Ontario's Bill 163 and Alberta's Bill 30 anchor the presumption to a closed list of designated occupations, Manitoba's legislation focused on the worker's exposure to traumatic events, with the presumption available to any covered worker who met the diagnostic criteria and the exposure conditions [Manitoba 2015].

The 2018 expansion: broadest scope in Canada

A 2018 amendment broadened the framework further. By making the presumption available to any worker exposed to traumatic events under specific conditions, rather than restricting it to a list of designated first-responder occupations, Manitoba's legislation became the most expansive PTSD presumption in Canada [WCB Manitoba 2024]. The practical consequence: industrial workers, healthcare workers outside designated nursing roles, social-service workers, and others who experience qualifying traumatic exposure in the course of their employment may benefit from the presumption, not only the police-fire-paramedic core.

What presumptive PTSD legislation does (and does not) do

It does:

Accelerate the underlying compensable PTSD diagnosis and WCB claim acceptance
Remove the burden on the worker to prove the PTSD is work-related
Speed access to mental-health treatment broadly, since the WCB claim is established faster

It does not:

Automatically approve any specific treatment, including ketamine or esketamine
Override the case-by-case review process for non-formulary therapies
Eliminate the need for documented conventional treatment failures and clinical rationale

For a deeper cross-provincial comparison, see the first-responder PTSD presumptive legislation in Canada guide. Manitoba workers pursuing ketamine-assisted therapy specifically for PTSD should also review ketamine therapy for PTSD and psychedelic therapy for PTSD for the underlying clinical evidence base.

How CPSM's January 2026 framework shapes WCB Manitoba ketamine claims

The College of Physicians and Surgeons of Manitoba (CPSM) is the provincial medical regulator. CPSM's authority extends to where, by whom, and under what conditions ketamine may be administered in Manitoba. In January 2026, CPSM rolled out an updated non-hospital facility framework governing the operation of medical facilities outside the hospital system, including those delivering ketamine therapy [CPSM 2026].

What the framework governs

The CPSM non-hospital facility framework sets standards for:

Facility registration and accreditation for non-hospital medical settings where procedures are performed
Clinical staffing requirements, including physician oversight and qualified clinical team members
Patient safety protocols, including monitoring, emergency response, and adverse event reporting
Recordkeeping and quality assurance standards

For ketamine therapy specifically, the practical implications are:

Intravenous and intramuscular ketamine must be administered in a facility that meets the non-hospital framework standards, with qualified physician oversight and appropriate monitoring.
Oral, sublingual, and intranasal ketamine are administered under different operational requirements, but still within the prescribing physician's scope of practice and standard of care.
Esketamine (Spravato) administration follows the Health Canada product monograph requirements, including the REMS-equivalent supervision protocol.

Ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label, regulated in Manitoba by CPSM. All ketamine-assisted therapy at ATMA CENA's Manitoba member clinic is delivered under physician oversight in compliance with current CPSM standards [CPSM 2026].

How the framework intersects with WCB Manitoba decisions

WCB Manitoba's medical advisors evaluate coverage requests against the standard of "reasonably required" healthcare services. A ketamine treatment plan delivered in a CPSM-compliant non-hospital facility, by a qualified prescribing physician, with documented clinical rationale and conventional treatment failures, presents a stronger file than one without. The CPSM framework does not automatically bind WCB Manitoba's decision, but it does establish the regulatory baseline for what constitutes appropriate clinical delivery in the province.

Manitoba Pharmacare lists Spravato as a non-benefit, which means provincial drug-plan reimbursement is unavailable for esketamine [Manitoba Pharmacare 2024]. For compensable workers, this increases the relative weight of the WCB claim pathway as the primary public reimbursement option. Workers without a compensable claim typically face out-of-pocket cost or private insurance review.

How to pursue a WCB Manitoba claim for ketamine therapy

The pathway from initial inquiry to potential treatment follows these stages:

Step 1: Establish the compensable diagnosis. For first responders and other workers covered by Manitoba's presumptive PTSD legislation, the underlying claim is accelerated by the legal presumption. For workers outside the presumption, the standard WCB Manitoba adjudication process applies. The worker files a claim, the treating physician documents the diagnosis (PTSD per DSM-5 criteria, chronic pain, treatment-resistant depression in the context of a workplace injury, or the relevant compensable condition), and WCB establishes claim acceptance.

Step 2: Document conventional treatment failures. Whether or not Manitoba publishes formal formulary criteria, the clinical question facing a WCB medical advisor is the same one any reviewer asks: have evidence-based first-line and second-line treatments been tried and documented? For PTSD, this typically means trauma-focused psychotherapy (CBT, EMDR, or equivalent) and pharmacotherapy. For chronic pain, this typically means a multimodal regimen including pharmacotherapy, physiotherapy, and where appropriate, interventional pain management. The treating physician records these trials and outcomes.

Step 3: Identify a prescribing physician. Ketamine for psychiatric and pain indications in Manitoba requires a prescribing physician who has the knowledge, skill, and judgment to do so safely, as required by CPSM. Psychiatrists, anaesthesiologists, chronic pain specialists, and physicians with relevant additional training are typical prescribers. The coordinated care partnership at NeuroMed Wellness Clinic in Winnipeg coordinates with prescribers operating within CPSM's framework.

Step 4: Submit the WCB request. The treating physician submits a written request to WCB Manitoba documenting the compensable diagnosis, prior treatment failures, the proposed ketamine treatment protocol, and the clinical rationale linking the proposed treatment to the compensable injury. The submission package may also include CPSM-compliant facility documentation and the prescribing physician's relevant credentials.

Step 5: WCB medical-advisor review. A WCB Manitoba medical advisor reviews the submission. The advisor may request additional information, recommend a specialist consultation, or make a coverage decision. Timelines vary based on complexity and documentation completeness.

Step 6: Coverage decision and treatment. WCB Manitoba issues a written decision. If approved, treatment is delivered in the qualifying clinical setting under physician oversight. If denied, the worker has appeal rights through WCB Manitoba's internal review process and, ultimately, the Appeal Commission for Workers Compensation.

For a comparison of how this case-by-case process differs from formal-listing provinces, see the WCB Alberta Procedure 4-12 process and the WSIB Ontario formulary pathway. For the neighbouring prairie context, see WCB Saskatchewan psychedelic therapy.

How ATMA CENA supports compensable Manitoba workers

ATMA CENA's role for injured Manitoba workers and first responders pursuing psychedelic-assisted therapy is the clinical delivery partner — not the WCB decision-maker. WCB Manitoba decides coverage; the treating physician submits the request; ATMA CENA supports the clinical infrastructure for assessment, preparation, dosing, and integration through its coordinated care partnership at NeuroMed Wellness Clinic in Winnipeg.

In practice, ATMA CENA's clinical process for WCB-referred Manitoba workers includes:

Intake and screening: An ATMA CENA practitioner reviews the clinical history, treatment records, and compensable diagnosis to assess appropriateness for ketamine-assisted therapy and to identify what additional documentation may strengthen the WCB submission.
Coordination with NeuroMed and the prescribing physician: Through the coordinated care partnership, the assessment, prescribing, and dosing components of treatment are delivered at NeuroMed Wellness Clinic in Winnipeg, in compliance with CPSM's January 2026 non-hospital facility framework.
Documentation support: ATMA CENA can prepare clinical documentation of treatment history and rationale to support the treating physician's WCB submission. ATMA CENA does not submit on behalf of the worker; only the treating physician may do so.
Integration support: Following dosing sessions, our clinical team supports the integration phase, coordinating with the worker's existing treaters (psychiatrist, psychologist, occupational health, EAP).

For workers whose WCB claim is under appeal or whose request is denied, ATMA CENA can assist with documentation that may support an appeal, in coordination with the treating physician and, where applicable, legal counsel.

For Winnipeg-specific access information, see psychedelic therapy in Winnipeg and ketamine therapy in Winnipeg. Veterans with service-related PTSD who are also exploring federal coverage should review VAC coverage for psychedelic-assisted therapy.

Frequently asked questions

Does WCB Manitoba cover psychedelic-assisted therapy?

WCB Manitoba reviews ketamine and esketamine treatment requests on a case-by-case basis. There is no formal published formulary or procedure analogous to WSIB Ontario's drug formulary or WCB Alberta's Procedure 4-12. Coverage depends on the specific compensable diagnosis, documented treatment history, and the medical advisor's review. Psilocybin and MDMA are not covered by WCB Manitoba; access is through Health Canada's Special Access Program on a case-by-case basis [WCB Manitoba 2024; Health Canada SAP].

Was Manitoba really the first province in Canada with presumptive PTSD legislation?

Yes. Manitoba's Workers Compensation Amendment Act (Presumption re Post-Traumatic Stress Disorder) was passed in January 2016 and came into force on June 9, 2016, making Manitoba the first Canadian province to enact a presumptive PTSD framework for workers' compensation. Other provinces, including Alberta (Bill 30, 2018) and Ontario (Bill 163, 2016, expanded 2024), followed [Manitoba 2015; WCB Manitoba 2016].

Who is covered by Manitoba's presumptive PTSD legislation?

The original 2016 legislation covered firefighters, police officers, paramedics, corrections officers, EMS dispatchers, sheriffs, and selected other workers exposed to traumatic events. A 2018 expansion broadened the framework to any worker exposed to traumatic events in the course of employment, under specific conditions, giving Manitoba the broadest presumptive PTSD scope in Canada [WCB Manitoba 2024].

Does presumptive PTSD eligibility automatically mean WCB will pay for ketamine therapy?

No. The presumption accelerates the underlying claim acceptance by removing the burden to prove the PTSD is work-related. It does not automatically approve any specific treatment, including ketamine or esketamine. A treatment-specific request, with clinical documentation and rationale, is still required.

What is the CPSM January 2026 framework and why does it matter?

In January 2026, the College of Physicians and Surgeons of Manitoba rolled out an updated non-hospital facility framework that governs how medical facilities outside the hospital system operate. The framework sets standards for facility registration, clinical staffing, patient safety, and recordkeeping. For ketamine therapy delivered in a non-hospital community clinic, compliance with the CPSM framework is the regulatory baseline. WCB Manitoba's coverage decisions are not bound by CPSM compliance, but a CPSM-compliant clinical delivery package is one element of a strong submission [CPSM 2026].

Is there a publicly funded outpatient ketamine programme in Manitoba?

No. Health Sciences Centre and St. Boniface Hospital provide inpatient mental health care, but there is no publicly funded outpatient psychiatric ketamine programme in Manitoba in 2026. Outpatient ketamine-assisted therapy is delivered through private clinics, with reimbursement available through compensable claims (WCB), federal benefits (e.g., VAC for veterans), private insurance where applicable, or out-of-pocket payment.

Does Manitoba Pharmacare cover Spravato (esketamine)?

No. Manitoba Pharmacare lists Spravato as a non-benefit, which means provincial drug-plan reimbursement is not available [Manitoba Pharmacare 2024]. For workers with a compensable claim, the WCB Manitoba pathway becomes the primary public reimbursement route for esketamine. For non-compensable patients, options are limited to private insurance review or out-of-pocket payment.

Can ATMA CENA submit the WCB Manitoba request on my behalf?

No. WCB Manitoba requires that medical treatment requests be submitted by the treating physician. ATMA CENA can prepare clinical documentation of treatment history and rationale to support the submission, but cannot act as the submitting party. The coordinated care partnership at NeuroMed Wellness Clinic in Winnipeg coordinates with prescribing physicians who can submit on the worker's behalf.

What happens if WCB Manitoba denies the request?

Workers have appeal rights through WCB Manitoba's internal review process. If the internal review upholds the denial, the worker may appeal to the Appeal Commission for Workers Compensation, which is independent of WCB. Additional clinical documentation, specialist consultations, or further documented treatment failures may strengthen an appeal. The Worker Advisor Office in Manitoba provides free advice and representation for injured workers in WCB matters.

Where in Manitoba can I access ketamine-assisted therapy through ATMA CENA?

Compliance notes

Ketamine off-label framing (required per CPSM and writing standards)

Ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label and regulated in Manitoba by the College of Physicians and Surgeons of Manitoba (CPSM). The CPSM updated its non-hospital facility framework in January 2026, setting the regulatory baseline for facilities delivering ketamine therapy outside the hospital system [CPSM 2026]. All ketamine-assisted therapy delivered through coordinated care partnership in Winnipeg is provided under physician oversight and in compliance with current CPSM standards.

Psilocybin and MDMA framing (required per Health Canada SAP notice)

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada's Special Access Program (SAP), on a case-by-case basis. SAP approval is granted at Health Canada's discretion and is not guaranteed. Psilocybin SAP is primarily approved for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA SAP is primarily approved for adults with PTSD. Approval rates declined approximately 50% in 2025 [PsyCan 2025; Health Canada SAP]. WCB Manitoba does not list psilocybin or MDMA. This article is for informational purposes only and does not constitute medical or legal advice.

Sources

WCB Manitoba (2024). About the WCB and Healthcare Services policies. Workers Compensation Board of Manitoba. https://www.wcb.mb.ca/
Government of Manitoba (2015). The Workers Compensation Amendment Act (Presumption re Post-Traumatic Stress Disorder), 2015. Manitoba Legislative Assembly. https://web2.gov.mb.ca/laws/statutes/2015/c01515e.php
WCB Manitoba (2016). PTSD Presumption: Information for Workers and Employers. Workers Compensation Board of Manitoba.
College of Physicians and Surgeons of Manitoba (2026). Non-Hospital Medical/Surgical Facility Framework — January 2026 update. CPSM. https://www.cpsm.mb.ca/
Manitoba Pharmacare (2024). Manitoba Drug Benefits and Interchangeability Formulary — Spravato listing status. Government of Manitoba. https://www.gov.mb.ca/health/mdbif/
Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Health Canada. Spravato (esketamine hydrochloride) Product Monograph. https://pdf.hres.ca/dpd_pm/00050959.PDF
PsyCan (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
Feder, A. et al. (2023). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry. https://pubmed.ncbi.nlm.nih.gov/37404970/
Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://pubmed.ncbi.nlm.nih.gov/33972795/
Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473–2480. https://pubmed.ncbi.nlm.nih.gov/37709999/
Chrenek, C., Duong, B., Khullar, A. et al. (Swainson, J.) (2024). Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Frontiers in Psychiatry, 14:1283733. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full

Workers' Compensation and Psychedelic-Assisted Therapy in Canada — cross-provincial comparison
Insurance Coverage for Psychedelic-Assisted Therapy in Canada — private and group insurance coverage overview
WCB Alberta Psychedelic-Assisted Therapy — Alberta's formal prior-authorization procedure
WSIB Ontario Psychedelic-Assisted Therapy — Ontario's formulary-based coverage framework
WCB Saskatchewan Psychedelic-Assisted Therapy — Saskatchewan workers' compensation coverage
First-Responder PTSD Presumptive Legislation in Canada — cross-provincial comparison of presumption frameworks
Psychedelic-Assisted Therapy in Winnipeg — Winnipeg clinic access
Ketamine Therapy in Winnipeg — Winnipeg ketamine therapy access
Ketamine Therapy for PTSD — PTSD evidence deep-dive
Psychedelic Therapy for PTSD — PTSD condition and treatment overview
VAC Coverage for Psychedelic-Assisted Therapy — federal coverage for veterans

Last updated: 2026-05-06. This article is reviewed every 3 months given time-sensitive regulatory and coverage information.

WCB Manitoba and Psychedelic-Assisted Therapy: Coverage, Process, and Presumptive PTSD (2026)

Coverage rules differ by payer